# A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetic Profile of a Single Doses of MMV533.

> **NCT04323306** · PHASE1 · COMPLETED · sponsor: **Medicines for Malaria Venture** · enrollment: 72 (actual)

## Conditions studied

- Malaria

## Interventions

- **DRUG:** MMV688533

## Key facts

- **NCT ID:** NCT04323306
- **Lead sponsor:** Medicines for Malaria Venture
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-12
- **Primary completion:** 2022-09-27
- **Final completion:** 2022-09-27
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2024-10-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04323306

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04323306, "A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetic Profile of a Single Doses of MMV533.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04323306. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*